New lipo-PGE1 using a stable prodrug of prostaglandin E1 (PGE1)

[1]  Y. Morizawa,et al.  A stable PGE1 prodrug for targeting therapy , 1992 .

[2]  D. Ingber,et al.  Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. , 1991, Biochemical and biophysical research communications.

[3]  K. Hongo,et al.  Immunohistochemically demonstrated increase of prostaglandin F2-alpha in neurons after reoxygenation in anoxic rats. , 1988, Prostaglandins.

[4]  H. Hashimoto,et al.  A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders. , 1987, The Journal of rheumatology.

[5]  F. Fitzpatrick,et al.  Albumin-eicosanoid interactions. A model system to determine their attributes and inhibition. , 1984, The Journal of biological chemistry.

[6]  Y. Mizushima,et al.  Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. , 1982, Annals of the rheumatic diseases.

[7]  M. Cho.  Reduced hydrolytic lability of epoprostenol in the presence of cationic micelles. , 1982, Journal of pharmaceutical sciences.

[8]  D. Papahadjopoulos,et al.  Covalent attachment of immunoglobulins to liposomes via glycosphingolipids. , 1981, Biochimica et biophysica acta.

[9]  D C Cardinal,et al.  The electronic aggregometer: a novel device for assessing platelet behavior in blood. , 1980, Journal of pharmacological methods.

[10]  G. Lunge.  Über die zweckmässigste Form des Gasvolumeters , 1891 .

[11]  Z. Óváry.  Immediate reactions in the skin of experimental animals provoked by antibody-antigen interaction. , 1958, Progress in allergy.